Intratumoral CAN2109 in Subjects With Solid Tumors
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
Solid Tumor|Lymphoma
DRUG: CAN2109
Safety, determined by assessment of dose limiting toxicities per protocol of CAN2109 with cancers., 12 months|Recommended Phase 2 Dose (RP2D), To determine a recommended phase 2 dose of CAN21909 for further development by evaluating number of patients with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)., 12 months|tolerability, determined by assessment of the maximum tolerated dose or maximal assessed dose per protocol of CAN2109 with cancers., 12 months
To determine the efficacy of CAN2109, Proportion of patients experiencing a tumor response or a stable disease according to RECIST 1.1 or iRECIST 1.1 as appropriate., 12 months|To evaluate the pharmacodynamics of CAN2109, Maximum observed plasma and tumor concentration of CAN2109 after IT administration., 12 months
The scope of the study is to evaluate the safety of CAN2109 in humans, explore its safety, efficacy and collect data on the pharmacokinetics, as well as on the pharmacodynamic effect of the drug on the immune system locally and systemically, and on tumor markers.